Trials / Completed
CompletedNCT00750178
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vorinostat (MK0683 ) | Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28 Total treatment period is 28 days |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2005-08-01
- Completion
- 2005-11-01
- First posted
- 2008-09-10
- Last updated
- 2017-04-07
Source: ClinicalTrials.gov record NCT00750178. Inclusion in this directory is not an endorsement.